Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate immunotherapies through its Cloudbreak® platform, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company will deliver a presentation on Wednesday, April 9, 2025, at 11:00 AM ET. The presentation will be accessible via webcast, with a replay available in the Investors section of Cidara's website for 90 days following the event.

Additionally, Cidara's management team will engage in one-on-one investor meetings during the conference. Interested investors should coordinate with their Needham representatives to schedule meetings.

News Market Reaction

-2.91%

1 alert

-2.91% News Effect

On the day this news was published, CDTX declined 2.91%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak^® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that company management will participate in the 24^th Annual Needham Virtual Healthcare Conference.

Details are as follows:

Event: 24^th Annual Needham Virtual Healthcare Conference
Date: Wednesday, April 9, 2025
Time: 11:00 AM ET
Format: Presentation
Webcast: https://wsw.com/webcast/needham146/cdtx/2261559

A replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.

Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara at the conference should contact their Needham representative directly.

About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The Company announced completion of enrollment of its 5000 patient Phase 2b NAVIGATE trial in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

FAQ

When is Cidara Therapeutics (CDTX) presenting at the Needham Healthcare Conference 2025?

Cidara Therapeutics will present on Wednesday, April 9, 2025, at 11:00 AM ET during the 24th Annual Needham Virtual Healthcare Conference.

How can investors access CDTX's Needham Conference presentation webcast?

Investors can access the webcast at https://wsw.com/webcast/needham146/cdtx/2261559 or view the replay in the Investors section on Cidara's website (www.cidara.com).

How long will CDTX's Needham Conference presentation replay be available?

The presentation replay will be available for 90 days in the Investors section of Cidara's website.

How can investors schedule one-on-one meetings with CDTX management at the Needham Conference?

Investors should contact their Needham representative directly to schedule one-on-one meetings with Cidara management.

What is the main technology platform that CDTX is developing?

Cidara Therapeutics is developing drug-Fc conjugate (DFC) immunotherapies using its proprietary Cloudbreak® platform.